Osimertinib Treatment Was Unsuccessful for Lung Adenocarcinoma with G719S, S768I, and T790M Mutations

Epidermal growth factor receptor (EGFR) T790M mutations are the most frequent mechanism of resistance to first- and second-generation tyrosine kinase inhibitors, and osimertinib is an effective treatment for patients with both EGFR-activating mutations and T790M resistance mutations. We describe the...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Intern Med
Main Authors: Nasu, Shingo, Shiroyama, Takayuki, Morita, Satomu, Takata, So, Takada, Hiromune, Masuhiro, Kentaro, Tanaka, Ayako, Morishita, Naoko, Suzuki, Hidekazu, Okamoto, Norio, Hirashima, Tomonori
Formato: Artigo
Idioma:Inglês
Publicado em: The Japanese Society of Internal Medicine 2018
Assuntos:
Case Report
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6355418/
https://ncbi.nlm.nih.gov/pubmed/30146570
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2169/internalmedicine.0923-18
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados